Beating Pain with Psychedelics: Matter over Mind?

Chronic pain involves persistent alterations in peripheral and central nervous system structure and function that affect sensory, emotional and cognitive domains and reduce physical, psychological and social well-being. Elman and colleagues note that pain becomes chronic when it persists or recurs for more than 3 months and estimate prevalence in US adults at around 30%, roughly 100 million people, with societal healthcare costs in the hundreds of billions of dollars. Traditional pharmacological approaches, notably opioids, have important limitations including uncertain long-term benefit, risk of opioid use disorder and adverse endocrine and affective consequences; these shortcomings, combined with a paucity of objective biomarkers for pain, motivate the search for new treatments. This review evaluates the hypothesis that psychedelic drugs could constitute a novel therapeutic avenue for chronic pain. Rather than focusing solely on their psychoactive effects, Elman and colleagues adopt a systems-based perspective that considers rapid and persistent changes in brain connectivity, synaptic plasticity, anti-inflammatory actions and modulation of descending pain pathways as putative mechanisms. The paper surveys preclinical and clinical evidence, highlights ketamine as a model compound, summarises limited clinical reports, and discusses regulatory, legal and ethical issues that bear on research and potential clinical use.

Elman and colleagues conducted a narrative literature evaluation rather than a formal systematic review. Searches were performed using PubMed, Google Scholar and Westlaw, and also involved identifying academic research centres and patient advocacy groups. Search terms combined “psychedelic” with pain-related keywords such as pain, analgesia, inflammatory, brain connectivity, ketamine and psilocybin, and reference lists of identified articles were scanned for additional sources. The extracted text does not report dates for the searches, explicit inclusion or exclusion criteria, the number or types of studies included, nor a formal risk-of-bias or quality assessment, so the review should be understood as a broad, integrative synthesis of published and grey literature. The authors organised the material around mechanistic domains (neurotransmitter/hormone actions, neural circuits, synaptic plasticity, anti-inflammatory effects), clinical reports and trials (including ketamine as a model), and regulatory and ethical considerations, integrating preclinical, neuroimaging and limited clinical data to build a conceptual “psychedelic hypothesis for analgesia.”

The review collates evidence that psychedelics can rapidly alter brain functional connectivity and may produce longer‑lasting changes in neural structure consistent with synaptic plasticity. Neuroimaging studies in healthy volunteers and patients indicate altered connectivity in cortical and subcortical regions implicated in pain processing (for example cingulate, medial prefrontal cortex, insula, thalamus and hippocampus). Preclinical and some human data suggest single administrations of certain psychedelics (notably ketamine and psilocybin) can increase markers of synaptogenesis or synaptic density and alter dendritic spine morphology, which the authors posit could help reverse maladaptive network states associated with chronic pain. Mechanistically, the paper summarises multiple putative pathways. Classical serotonergic psychedelics act primarily at the 5‑HT2A receptor, with downstream effects on glutamatergic and GABAergic signalling and regional changes in glutamate levels; ketamine acts principally as an NMDA antagonist but also produces rapid antidepressant, anti-inflammatory and spine‑remodelling effects. Anti‑inflammatory actions are highlighted: ketamine inhibits proinflammatory cytokines such as TNF‑alpha, IL‑6 and IL‑8 in vitro and has been reported to modulate astrocyte activation and neurotrophic factors (for example BDNF). The authors discuss the possibility that psychedelics influence descending modulatory systems (cortico‑brainstem circuits involving anterior cingulate, raphe nuclei and periaqueductal gray), and note limited and mixed evidence on interactions with opioidergic systems. Clinical evidence for analgesia is currently sparse and heterogeneous. Ketamine has been used in various chronic pain conditions (neuropathic pain, complex regional pain syndrome, among others) with documented analgesic effects but also recognised risks. For classical psychedelics such as psilocybin and LSD the literature consists mostly of case reports, small series and experimental studies; examples include reported benefit in cluster headache and phantom limb pain, and a low‑dose LSD trial that decreased pain perception in healthy volunteers. The authors note countervailing preclinical signals too—some 5‑HT2A activity can be pro‑nociceptive in certain models—so net clinical effects may vary by drug, dose, condition and context. Across the review, Elman and colleagues emphasise the absence of robust randomised controlled trials in chronic pain and gaps concerning optimal dosing regimens, the role of subjective psychedelic experiences versus non‑psychoactive mechanisms, safety in vulnerable patients, and long‑term outcomes.

Elman frames psychedelics as candidate analgesics that may act through multiple, potentially synergistic mechanisms: acute reorganisation of brain networks (the so‑called ‘‘shock’’ or resetting effect), induction of synaptic plasticity that may persist beyond drug clearance, modulation of neuroinflammatory processes, and alteration of affective and cognitive contributors to pain. The authors draw parallels with ketamine, which provides both a clinical precedent and mechanistic insights, and they discuss how psychedelic‑induced changes in connectivity and dendritic structure could theoretically normalise circuits that maintain chronic pain. Relative to prior literature, the review situates psychedelics within a broader shift towards targeting brain network dysfunction in CNS disorders and highlights the potential overlap between mechanisms relevant to depression, addiction and chronic pain. Important uncertainties are acknowledged: evidence in humans is limited and largely preliminary, receptor‑specific actions (for example 5‑HT2A) have complex and sometimes contradictory roles in nociception, and it remains unclear whether subjective psychedelic experiences are necessary for analgesic benefit. The authors also underscore non‑scientific barriers, including Schedule I legal restrictions that constrain research, equity concerns about access and patenting, and ethical issues around informed consent for potentially transformative subjective experiences. Practical implications emphasised by the authors include the need for rigorous, placebo‑controlled trials to establish safety and efficacy in chronic pain, exploration of non‑hallucinogenic analogues or combinations that may retain therapeutic properties without psychoactive effects, and concurrent development of regulatory and credentialling frameworks to ensure equitable and safe clinical deployment. The review repeatedly notes the preliminary nature of current data and calls for mechanistically informed translational research to move from anecdote to evidence.

Elman and colleagues conclude that psychedelics hold conceptual promise as analgesics through both psychoactive and non‑psychoactive mechanisms—network resetting, synaptic plasticity and anti‑inflammatory effects among them—but that this promise remains unproven. They propose concrete research priorities: (a) development and testing of purified or transformed psychedelic‑like compounds that lack hallucinatory effects, (b) study of serotonergic agents alone or in combination with psychedelics to safely augment neurotransmission, and (c) establishment of legal and ethical regulations to balance access, safety and research needs. Ultimately, the authors state, the value of the “psychedelic hypothesis for analgesia” will depend on whether future mechanistic and clinical studies demonstrate safe, reproducible and clinically meaningful benefits for people with chronic pain.